22nd Century Group reported net sales revenue of $7.3 million for Q4 2020, consistent with the prior-year period. The company's gross profit improved, while the net loss increased. The company is focused on securing Modified Risk Tobacco Product (MRTP) authorization for VLN® and advancing its hemp/cannabis strategy.
Net sales revenue for the fourth quarter was $7.3 million, consistent with the prior-year period.
Gross profit for the fourth quarter improved by $364 thousand.
Net loss increased by $207 thousand for the fourth quarter.
The company's balance sheet is well funded with $22.3 million at the end of the year.
22nd Century Group is focused on securing FDA authorization for VLN®, supporting the FDA’s plan to require all cigarettes sold in the U.S. to be made “minimally or non-addictive”, targeting the upstream segment of the cannabinoid value chain, developing a third, plant-based franchise after securing MRTP authorization for VLN®, and maintaining diligent financial execution.